{"title":"关于西班牙骨关节炎使用和资助 SYSADOA 的争议：媒体上的科学-社会辩论分析。","authors":"Pedro Alfonso Domínguez Vera , Luis Carrasco Páez","doi":"10.1016/j.reumae.2024.09.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and objective</h3><div>The use of SYmptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) in the treatment of osteoarthritis (OA) has been a topic of debate in the scientific community and public entities regarding their public financing in Spain. The objective of this study was to describe and analyse the main positions of media outlets, public entities, regarding the use and financing of SYSADOA in Spain.</div></div><div><h3>Methods</h3><div>A qualitative and quantitative analysis of the content regarding the use and financing of SYSADOA was conducted in general media outlets (<em>El País</em>, <em>El Mundo, La Vanguardia, ABC,</em> and <em>20minutos</em>), public statements, and Twitter publications.</div></div><div><h3>Results</h3><div>A total of 15 articles in general media outlets, 872 tweets, and 7 public entity statements were identified. Mostly, media outlets (91%) and social media platforms (78%) exhibited a favorable trend towards funding.</div></div><div><h3>Discussion and conclusions</h3><div>The use of SYSADOA in OA patients continues to be controversial in the scientific community. However, there is consensus among patient associations in favour of public funding and use as a treatment for OA patients.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 8","pages":"Pages 416-422"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Controversy about the use and financing of SYSADOA for osteoarthritis in Spain: An analysis of the scientific-social debate in the media\",\"authors\":\"Pedro Alfonso Domínguez Vera , Luis Carrasco Páez\",\"doi\":\"10.1016/j.reumae.2024.09.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background and objective</h3><div>The use of SYmptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) in the treatment of osteoarthritis (OA) has been a topic of debate in the scientific community and public entities regarding their public financing in Spain. The objective of this study was to describe and analyse the main positions of media outlets, public entities, regarding the use and financing of SYSADOA in Spain.</div></div><div><h3>Methods</h3><div>A qualitative and quantitative analysis of the content regarding the use and financing of SYSADOA was conducted in general media outlets (<em>El País</em>, <em>El Mundo, La Vanguardia, ABC,</em> and <em>20minutos</em>), public statements, and Twitter publications.</div></div><div><h3>Results</h3><div>A total of 15 articles in general media outlets, 872 tweets, and 7 public entity statements were identified. Mostly, media outlets (91%) and social media platforms (78%) exhibited a favorable trend towards funding.</div></div><div><h3>Discussion and conclusions</h3><div>The use of SYSADOA in OA patients continues to be controversial in the scientific community. However, there is consensus among patient associations in favour of public funding and use as a treatment for OA patients.</div></div>\",\"PeriodicalId\":94193,\"journal\":{\"name\":\"Reumatologia clinica\",\"volume\":\"20 8\",\"pages\":\"Pages 416-422\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reumatologia clinica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2173574324001126\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia clinica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173574324001126","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Controversy about the use and financing of SYSADOA for osteoarthritis in Spain: An analysis of the scientific-social debate in the media
Background and objective
The use of SYmptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) in the treatment of osteoarthritis (OA) has been a topic of debate in the scientific community and public entities regarding their public financing in Spain. The objective of this study was to describe and analyse the main positions of media outlets, public entities, regarding the use and financing of SYSADOA in Spain.
Methods
A qualitative and quantitative analysis of the content regarding the use and financing of SYSADOA was conducted in general media outlets (El País, El Mundo, La Vanguardia, ABC, and 20minutos), public statements, and Twitter publications.
Results
A total of 15 articles in general media outlets, 872 tweets, and 7 public entity statements were identified. Mostly, media outlets (91%) and social media platforms (78%) exhibited a favorable trend towards funding.
Discussion and conclusions
The use of SYSADOA in OA patients continues to be controversial in the scientific community. However, there is consensus among patient associations in favour of public funding and use as a treatment for OA patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
